aldafermin

Aldafermin is an engineered analogue of the human hormone fibroblast growth factor 19 (FGF19), developed as a potential treatment for chronic liver diseases such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and primary biliary cirrhosis. It acts primarily by binding to the Fibroblast growth factor receptor 4 (FGFR4)-KLB receptor complex on hepatocytes to potently suppress cholesterol 7α-hydroxylase (CYP7A1), thereby inhibiting bile acid synthesis. This mechanism reduces toxic hydrophobic bile acids that contribute to liver injury and fibrosis. Aldafermin also activates the Fibroblast growth factor receptor 1c (FGFR1c)-KLB receptor pathway, improving insulin sensitivity and energy metabolism. The drug is being developed by NGM Biopharmaceuticals and has received orphan drug status for certain rare liver diseases[1][2][4][5][6].

Brand names

aldafermin

Other names

(phe5>met,ser6>arg,ala8>ser,gly9>ser,his11>leu) fibroblast growth factor 19 human fgf19 5-194-peptide produced in escherichia coliengineered variant of recombinant human fibroblast growth factor 19